Checking in with Cytokinetics ahead of the SEQUOIA-HCM P3 study result due in December
- blonca9
- Nov 20, 2023
- 1 min read
President and CEO Robert Blum describes aficamten's mechanism, the trial's study design, and reflects on Cytokinetics' journey of 25 years in drug development.